Carbohydrate antigen 19-9-positive prostatic ductal adenocarcinoma effectively treated with cisplatin and gemcitabine.

Abstract

We performed a radical retropubic prostatectomy on a 59-year-old male patient who was diagnosed with prostatic carcinoma. Pathological findings revealed a ductal adenocarcinoma in the left lobe of the prostate, and a conventional well-differentiated adenocarcinoma in the right lobe. Immunohistochemistry revealed that CA19-9 was positive in the ductal adenocarcinoma, and prostate-specific antigen was positive in the conventional well-differentiated adenocarcinoma. Since there was an increase in the level of serum CA19-9, which had decreased postoperatively, along with the appearance of local recurrence and bone metastasis, we treated the patient with cisplatin and gemcitabine. As a result, the level of serum CA19-9 was normalized and a reduction of the metastatic focus was observed.

• Authors: Toshiki Kato, Yoshihiro Hashimoto, Shinsuke Okada, Keiichi Tozawa, Satoru Takahashi, Kenjiro Kohri
• Journal: International journal of urology : official journal of the Japanese Urological Association (Int J Urol) Vol. 14 Issue 12 Pg. 1103-6 (Dec 2007) ISSN: 0919-8172 [Print] Australia
• PMID: 18036053 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• CA-19-9 Antigen
• Deoxycytidine
• Cisplatin
• Gemcitabine

Topics

• Adenocarcinoma (drug therapy)
• Antineoplastic Agents (administration & dosage, therapeutic use)
• CA-19-9 Antigen (genetics, metabolism)
• Cisplatin (administration & dosage, therapeutic use)
• Deoxycytidine (administration & dosage, analogs & derivatives, therapeutic use)
• Drug Therapy, Combination
• Humans
• Male
• Middle Aged
• Prostatic Neoplasms (drug therapy)
• Gemcitabine